Levalbuterol versus albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis

CONCLUSION: Levalbuterol is a cost-saving option for treating hospitalized patients with COPD in China.PMID:35786135 | DOI:10.1080/13696998.2022.2096892

Source: Journal of Medical Economics - July 5, 2022 Category: Health Management Authors: Lei Chen Xianqiu Chen Canghong Zhi Xuan Li Yang Hu Source Type: research